4-pentyl-3-cyclohexen-1-carboxylic acid | 155468-69-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-pentyl-3-cyclohexen-1-carboxylic acid
• 英文别名: 4-Pentyl-3-cyclohexenylcarboxylic acid；4-pentylcyclohex-3-ene-1-carboxylic acid
• CAS: 155468-69-2
• 化学式: C₁₂H₂₀O₂
• 分子量: 196.29
• InChiKey: QYDJJKOFZURXAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-pentyl-3-cyclohexen-1-carboxylic acid 在 lithium 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 4-pentyl-3-cyclohexen-1-methanol
  参考文献：
  名称：

  Ferroelectric liquid crystal compounds with cyclohexenyl cores and

  摘要：

  提供了含有环己烯衍生物的铁电液晶化合物和组合物。具体提供的是以下式的化合物：其中R.sub.1和R.sub.2可以是具有一到约二十个碳原子的烷基、环烷基、烯基、烷氧基、硫代烷基、烷基硅基基团。Y表示--COO--、--OOC--、--CH.sub.2 O--或--OCH.sub.2 --；Ar.sub.1和Ar.sub.2彼此独立地可以从苯环、卤代苯环和含氮芳基组成的群中选择。在本发明的优选实施例中，这些化合物至少含有一个含氮芳香环。Ar.sub.1和Ar.sub.2可以从1,4-苯基、单卤代或双卤代1,4-苯基、2,5-吡啶基、2,5-嘧啶基、2,5-吡嗪基、2,5-噻二唑基、3,6-吡啶并吡嗪基和1,4-环己基中选择，其中一个或两个可以是手性的外消旋群或手性的非外消旋群。

  公开号：

  US05271864A1
• 作为产物：
  描述：

  正戊基溴化镁 在 2) alkali 作用下， 反应 9.5h， 生成 4-pentyl-3-cyclohexen-1-carboxylic acid
  参考文献：
  名称：

  Bezborodov, V. S.; Konovalov, V. A.; Lapanik, V. I., Journal of Organic Chemistry USSR (English Translation), 1988, vol. 24, # 3, p. 551 - 554

  摘要：

  DOI：

文献信息

• ARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES
  申请人：Dolente Cosimo

  公开号：US20110245237A1

  公开（公告）日：2011-10-06

  The present invention is concerned with aryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I wherein R 1 , R 2 and R 3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The compounds are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I的芳基-环己基-四氮杂苯并[e]吲哚类化合物 其中R1，R2和R3如本文所述。本发明进一步提供了制造此类化合物的方法和包含它们的药物组合物。根据发明的化合物作为V1a受体调节剂，特别是作为V1a受体拮抗剂。这些化合物作为治疗剂在周围和中枢条件下对痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、血管加压素分泌不当、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和攻击性行为是有用的。
• [EN] ARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES<br/>[FR] ARYL-CYCLOHEXYL-TÉTRAAZABENZO[E]AZULÈNES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011120877A1

  公开（公告）日：2011-10-06

  The present invention is concerned with aryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I, wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as Via receptor modulators, and in particular as Via receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I的芳基-环己基-四氮杂苯并[e]吲哚类化合物，其中R1，R2和R3如本文所述。根据发明的化合物作为Via受体调节剂，特别是作为Via受体拮抗剂，它们的制造，含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂，在痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、不适当的血管升压素分泌、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和攻击性行为的条件中，在周围和中心部位发挥作用。
• ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES
  申请人：Dolente Cosimo

  公开号：US20110251183A1

  公开（公告）日：2011-10-13

  The present invention is concerned with aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes of formula I wherein R 1 , R 2 and R 3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1 a receptor modulators, and in particular as V1 a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I的芳基/杂芳基环己烯基四氮杂苯并[e]吲哚啉类化合物 其中R1，R2和R3如本文所述。本发明还提供了制造此类化合物的方法和含有它们的药物组合物。根据发明的化合物作为V1a受体调节剂，特别是作为V1a受体拮抗剂，它们的制造，含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂在末梢和中央条件下痛经，男性或女性性功能障碍，高血压，慢性心力衰竭，不适当的抗利尿激素分泌，肝硬化，肾病综合征，焦虑，抑郁障碍，强迫症，自闭症谱系障碍，精神分裂症和侵略性行为中是有用的。
• [EN] ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E] AZULENES AS VASOPRESSIN ANTAGONISTS<br/>[FR] ARYL-/HÉTÉROARYL-CYCLOHEXÉNYL-TÉTRAAZABENZO[E]AZULÈNES EN TANT QU'ANTAGONISTES DE VASOPRESSINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011128265A1

  公开（公告）日：2011-10-20

  The present invention is concerned with aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes of formula I wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I的芳基/杂芳基环己烯基四氮杂苯并[e]吲哚啉，其中R1、R2和R3如本文所述。根据发明的化合物作为V1a受体调节剂，尤其是作为V1a受体拮抗剂，它们的制造、含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂，在痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、不适当分泌的抗利尿激素、肝硬化、肾病综合征、焦虑症、抑郁症、强迫症、自闭症谱系障碍、精神分裂症和侵略性行为的条件下，在周围和中心发挥作用。
• Cyclohexyl- and cyclohexenyl-substituted liquid crystals with low birefringence
  申请人：Displaytech, Inc.

  公开号：US06413448B1

  公开（公告）日：2002-07-02

  A liquid crystal composition comprising a host material and a low birefringence liquid crystal composition of the formula: R1—Ar—R2 wherein R1 and R2, independently of one another, are selected from the group consisting of internally branched alkyl groups having from 4 to 20 carbon atoms, terminally branched alkyl groups having from 3 to 20 carbon atoms, internally branched alkenyl groups having from 3 to 20 carbon atoms and terminally branched alkenyl groups having from 4 to 20 carbon atoms, wherein one or more —CH2— groups in R1 and R2 may be independently replaced with O, said R1 or R2, independently of one another, can be partially or fully halogenated, and wherein one or both of said R1 and R2 can be absent; Ar is a ring core moiety of the general formula: wherein Cyc is a cyclohexyl ring or a cyclohexenyl ring; RX is a phenyl ring which may be optionally substituted with one or more fluorines; RY is a cyclohexyl or cyclohexenyl ring; wherein x and y are 1 and z is 0; wherein A is COO; and B is selected from the group of small alkyl or alkenyl group having from 1 to 8 carbon atoms, COO and OCO; wherein a and b are 1 and d is zero.

  一种液晶组合物，包括宿主材料和低双折射液晶组合物，其化学式为：R1—Ar—R2，其中R1和R2独立地选自以下组中的一种：内部支链烷基，碳数为4到20；末端支链烷基，碳数为3到20；内部支链烯基，碳数为3到20；末端支链烯基，碳数为4到20；其中R1和R2中的一个或多个—CH2—基团可以独立地被O取代，R1或R2中的一个或两个可以部分或完全卤代，其中R1和R2中的一个或两个可以不存在；Ar是一个环核心基团，通式为：其中Cyc是一个环己基环或环己烯基环；RX是苯环，可以选择性地被一个或多个氟取代；RY是环己基或环己烯基环；其中x和y为1，z为0；其中A为COO；B选自具有1到8个碳原子的小烷基或烯基组，COO和OCO之一；其中a和b为1，d为零。